Updates to CancerKB

June 2022

In the June 2022 CancerKB release, updated were made to the ERBB2 and PTEN genes.

  • 13 new interpretations were added for the ERBB2 gene. Interpretations include new drug sensitivity and resistance interpretations in colorectal adenocarcinoma, non-small cell lung cancer, and esophagogastric adenocarcinoma.
  • Several updates were made to the interpretations associated with the PTEN gene including adding tier I drug sensitivity for glioblastoma, colorectal adenocarcinoma, and prostate adenocarcinoma. Tier II level drug sensitivity has been updated for breast carcinoma, and tier II level drug resistance has been added for colorectal adenocarcinoma.

March 2022

In the March 2022 CancerKB release, 37 new features were added.

  • Interpretation re-work and refinement of drug sensitivity and resistance sections were a focus of this month’s release and will be a focus for upcoming releases of CancerKB. The curators are removing resistance interpretations that are not biomarker specific. For example, certain kinase inhibitors that are used to treat BRAF V600 mutations, such as Vemurafenib. Overtime, patients treated with these inhibitors can develop resistance to the therapy. However a patient is not resistant to to the kinase inhibitors because of the BRAF V600 mutation, so we are removing these interpretations. An example of a biomarker specific resistance therapy is patients that have the biomarker BTK C481. Patients with lymphoid neoplasms and a mutation in this codon are resistant to BTK inhibitors, Ibrutinib, acalabrutinib, and zanubrutinib.
  • Updates have been made to BRAF, PDGFRA/B, and ALK related interpretations updating resistance and drug sensitivity interpretations. A new “Activating mutation” interpretation has been added for ALK in Non-Small Cell Lung cancer.
  • A new drug, pacritinib, was approved by the FDA on March 1st for the treatment of patients with myeloid neoplasm and the JAK2 V617F mutation. The drug sensitive interpretation has been updated to include this drug. JAK2 gene summary, outcomes and frequency, and biomarker sections have been updated as well.

February 2022

In the February 2022 CancerKB release, 37 new features were added.

  • Several updates were made to BRAF related interpretations including new interpretations for Outcomes and Frequencies and Biomarkers Summaries with clinical evidence for several new cancer types.
  • New interpretations have been added for FGFR2 and IDH-1 in Cholangiocarcinoma, and FGFR3 in Bladder Urothelial Carcinoma.
  • New “Activating” and “Loss” biomarker interpretations have been added for some genes.

January 2022

In the January 2022 CancerKB release, 65 new features were added.

  • Several new cancer gene summaries
  • New loss of function biomarker interpretation for prostate adenocarcinoma for CDK12. This interpretation contains tier level I drug sensitivity, prognostic, and diagnostic info.
  • New loss of function biomarker interpretation for fallopian tube carcinoma and pancreatic adenocarcinoma for BRCA1 and BRCA2. These interpretations contain tier level I drug sensitivity, drug resistance, prognostic, and diagnostic info.
  • Updated gene and outcomes and frequency interpretations for several genes
Updated on June 20, 2022

Was this article helpful?

Related Articles

Leave a Comment